Form 4: STAAR Surgical Director Zhou Lilian Yansheng Reports Acquisition and Disposal of Shares

Director Zhou Lilian Yansheng reported acquiring shares of STAAR Surgical Co. through restricted stock and options grants, while also disposing of shares.

Summary

• On June 20, 2024, Lilian Zhou, a director of STAAR Surgical Co., reported transactions involving the company's stock.
• Zhou acquired 2,244 shares of common stock at $0.00 and disposed of 4,571 shares.
• Additionally, Zhou acquired options to purchase 4,010 shares of common stock at an exercise price of $40.11.
• These options are exercisable from June 20, 2025, and expire on June 19, 2034.
• Following these transactions, Zhou directly owns 4,010 derivative securities.
• The restricted stock and options were granted under the company's annual non-employee director equity compensation program for the 2024-2025 term and vest fully on the earlier of June 20, 2025, or the company's 2025 Annual Meeting of Shareholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions related to equity compensation. The acquisition of shares and options is mildly positive, while the disposal of shares is mildly negative, balancing out overall.

Positives

• The grant of restricted stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's long-term success.

Negatives

• The disposal of 4,571 shares by the director could be interpreted negatively by some investors, although the reason for disposal is not specified.

Risks

• The vesting of the equity awards is contingent on the director's continued service, which introduces a risk if the director were to leave the company before the vesting date.
• Market fluctuations could impact the value of the underlying common stock, affecting the value of the options.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the equity awards.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Equity compensation is a standard practice to incentivize directors and align their interests with shareholders. Companies like Alcon, Johnson & Johnson, and Bausch + Lomb also utilize similar equity compensation programs for their directors.

Comparison to Industry Standards

• Equity compensation for directors is a common practice across the medical device industry.
• Companies like Alcon, Johnson & Johnson, and Bausch + Lomb also utilize similar equity compensation programs for their directors.
• The specific terms of the grants, such as vesting schedules and exercise prices, are generally aligned with industry norms to attract and retain qualified board members.

Stakeholder Impact

• The equity compensation program aims to align the interests of the director with those of the shareholders, potentially leading to better corporate governance and decision-making.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates